Amendments to the Specification:

Please amend the specification as follows:

Please replace the paragraphs starting at page 8, line 11, through page 9, line 18, with the following paragraphs:

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Shows a graph of the cumulative % drug (naproxen) released over time using a nanoparticulate composition comprising 30% Klucel® hydroxypropylcellulose (HPC) and 3% polyvinylpyrrolidone (PVP);

Figure 2: Shows a graph of the cumulative % drug (naproxen) released over time for three different nanoparticulate compositions having a hardness of 15, 25, and 35 kP;

Figure 3: Shows a graph of the cumulative % drug (naproxen) released over time for nanoparticulate compositions comprising different types of hydroxypropyl methylcellulose (HPMC);

Figure 4: Shows a graph of the cumulative % drug (naproxen) released over time for nanoparticulate compositions comprising one of six different types of HPMC;

Figure 5: Shows a graph of the cumulative % drug (naproxen) released over time for nanoparticulate compositions having varying amounts Lubritab® (a hydrogenated vegetable oil);

Figure 6: Shows a graph comparing the cumulative % drug (naproxen) released over time for a spray-dried nanoparticulate formulation and a formulation of blended raw drug and stabilizer;

Figure 7: Shows a graph comparing the cumulative % drug (naproxen) released over time for nanoparticulate formulations comprising different concentrations of Methocel® K100LV (HPMC);

Figure 8: Shows a graph comparing the cumulative % drug (naproxen) released over time for directly compressed and wet granulated nanoparticulate

formulations of Klucel® and Methocel®; and

Figure 9: Shows the controlled release of nanoparticulate glipizide from directly compressed Methocel® tablets.

Figure 10: Shows the mean *in vivo* plasma profiles of nifedipine after single dosed, fasted, administration in humans for (1) nifedipine containing controlled release matrix tablets coated with a controlled release coating according to the present invention as described in Example 12; and (2) a control composition.

Figure 11: Shows the mean *in vivo* plasma profiles of nifedipine after single dosed, fasted, administration in humans for (1) a nifedipine controlled release composition manufactured according to the present invention as described in Example 14; and (2) a control composition.

Figure 12: Depicts the comparison of the plasma concentration of nifedipine having a D_{90} particle size of 500 nm with that of nifedipine having a D_{90} particle size of 186 μm over a period of 24 hours after administration.